REG - Creo Medical Group - Director/PDMR Shareholding
RNS Number : 2903LCreo Medical Group PLC09 September 2021Creo Medical Group plc
("Creo" or the "Company")
Director/PDMR Shareholding
Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces that Charles Spicer, Non-Executive Chairman, purchased 9,657 Ordinary Shares through the Open Offer at the Offer Price of 182.5 pence per Ordinary Share via his Self-Invested Personal Pension ('SIPP'). Following this purchase and Admission of the New Ordinary Shares on 7 September 2021 Charles Spicer holds 127,976 Ordinary Shares in the Company via his SIPP, representing approximately 0.07% of the Company's issued share capital.
Capitalised terms used, but not defined in this announcement shall have the same meaning as set out in the Circular dated 16 August 2021.
Creo Medical Group plc
Richard Rees (CFO)
+44 (0)1291 606 005
Cenkos Securities plc
+44 (0)20 7397 8900
Stephen Keys / Camilla Hume (NOMAD)
Michael Johnson / Russell Kerr (Sales)
Walbrook PR Ltd
Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com
Paul McManus / Lianne Cawthorne
Mob: +44 (0)7980 541 893 / +44 (0)7515 909 238
The information below, set out in accordance with the requirements of the MAR, provides further detail.
ANNEX
Template for notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Charles Spicer
2
Reason for the notification
a)
Position/status
Non-Executive Chairman
b)
Initial notification /Amendment
Initial
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Creo Medical Group plc
b)
LEI
213800H188ZDCWWXFA21
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Identification code
Ordinary Shares of £0.001 each
GB00BZ1BLL44
b)
Nature of the transaction
Purchase of shares
c)
Price(s) and volume(s)
Price(s)
Volume(s)
182.5p
9,657
d)
Aggregated information
- Aggregated volume
- Price
N/A
e)
Date of the transaction
7 September 2021
f)
Place of the transaction
London Stock Exchange
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDDSHFLFFIAIIAIIL
Recent news on Creo Medical
See all newsRCS - Creo Medical Group - U.S. FDA clearance for SpydrBlade™ Flex
AnnouncementREG - Creo Medical Group - Director/PDMR Shareholding
AnnouncementREG - Creo Medical Group - Posting of AR&R and Notice of AGM
AnnouncementREG - Creo Medical Group - US Reimbursement milestone for Speedboat procedure
AnnouncementREG - Creo Medical Group M&G PLC - Holding(s) in Company
Announcement